Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 82.50
High: 82.50
Low: 82.50
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

13 Feb 2015 07:00

RNS Number : 8129E
Feedback PLC
13 February 2015
 

FEEDBACK PLC

 

Feedback plc

("Feedback", the "Company" or the "Group")

 

Interim Report for the six months ended 30 November 2014

 

Chairman's Statement

 

We are pleased to present the results for the six months ended 30 November 2014. This is the first set of results that includes the trading of the two medical imaging companies, Cambridge Computed Imaging Limited ('CCI') and TexRAD Limited, (TexRAD) acquired in May 2014.

 

Revenue for the six month period was £229,000 (2013: non trading) and the loss after tax was £219,000. (2013: loss of £471,000). The loss before interest, tax and amortisation was £138,000 (2013: Loss £471,000). The cash balance at 30 November 2014 was £268,000, (2013: £696,000) which was after the payment of certain overdue creditors totalling £189,000 owed by CCI.

 

During this period, significant progress has been made with CCI achieving ISO 13485, the International Standard relating to quality management systems for organisations involved in the manufacture of medical devices.

 

TexRAD has been granted a European patent. The Group continues to make progress towards the launch later this year of a commercial version of its TexRAD software for the pharmaceutical trials market which is expected to be achieved following 21 CFR 11 self certification in the second quarter of 2015. We will continue to work with our distributor to gain momentum in this market.

 

The FDA approval application for the Group's software systems has been a more difficult process than anticipated due to the new procedures. We anticipate that the application will be made during the second quarter of 2015.

 

The Group has invested in people over the period. Two new staff were appointed during the six months under review, with a further two joining before the year end to prepare the business for commercial sales of the products.

 

We continue to look to develop the Group's presence in the medical imaging sector through acquisitions and collaborations with research institutions. We can offer software systems and regulatory assistance for new medical imaging techniques which will assist the process of bringing them to market.

 

2015 is expected to be a year of transition for the Company as it moves from development to commercialisation with its TexRAD product.

 

Simon Barrell

Chairman

 

 

Enquiries:

Feedback plc

Simon Barrell

Tom Charlton

Trevor Brown

 

Tel: 01954 718072

Sanlam Securities UK Limited (Nominated adviser)

Simon Clements/Virginia Bull

 

Tel: 020 7628 2200

 

 

 

UNAUDITED CONSOLIDATED INCOME STATEMENT

 

 

6 months to

30 November 2014

6 months to

30 November 2013

Year to 31 May

2014

 

£'000

£'000

£'000

Revenue

229

-

7

Cost of sales

(42)

-

-

Gross profit

187

-

7

Other operating expenses

(415)

(114)

(314)

Costs associated with the acquisition of subsidiaries

 

-

 

-

 

(164)

Total operating expenses

(415)

(114)

(478)

Operating loss

(229)

(114)

(471)

Losses on disposal of discontinued operations

-

-

-

Finance costs

-

(8)

-

Loss before tax

(229)

(122)

(471)

Tax credit/(expense)

10

-

-

Loss for the period attributable to the equity shareholders of the parent Loss on ordinary activities after tax

 

 

(219)

 

 

(122)

 

 

(471)

Other comprehensive income/(expense)

Translation differences on overseas operations

 

-

 

(14)

 

(3)

Total comprehensive expense for the period

 

(219)

 (136)

 

(474)

Basic and diluted earnings per share

 

2

 

(0.011p)

 

(0.09p)

 

(0.27p)

 

 

 

 

 

UNAUDITED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

 

 

Share Capital

Share Premium

Capital Reserve

Retained Earnings

Translation Reserve

Convertible Debt Option Reserve

Total

£'000

£'000

£'000

£'000

£'000

£'000

£'000

Balance at 31 May 2013

327

851

300

(510)

(207)

-

761

Total comprehensive income for the period

 

-

 

-

 

-

 

(122)

 

(14)

 

-

 

(136)

Balance at 30 November 2013

327

851

300

(632)

(221)

-

625

New shares issued

150

598

-

-

-

-

748

Costs associated with the raising of funds

 

-

 

(40)

 

-

 

-

 

-

 

-

 

(40)

Share option and warrant costs

-

-

14

-

-

14

Convertible debt raised in the year

-

-

-

-

-

189

189

Total comprehensive expense for the period

 

-

 

-

 

-

 

(349)

 

11

 

-

 

(338)

Balance at 31 May 2014

477

1,409

300

(967)

(210)

189

1,198

Share option and warrant costs

-

-

-

3

-

-

3

Total comprehensive income for the period

 

-

 

-

 

-

 

(219)

 

-

 

-

 

(219)

Balance at 30 November 2013

477

1,409

300

(1,183)

(210)

189

982

 

UNAUDITED CONSOLIDATED BALANCE SHEET

 

 

 

30 November 2014

30 November 2013

31 May

2014

 

£'000

£'000

£'000

ASSETS

 

Non-current assets

Property, plant and equipment

6

-

1

Intangible assets

839

-

848

 

 

845

-

849

 

Current assets

Trade receivables

160

-

87

Other receivables

73

17

121

Cash and cash equivalents

268

696

874

 

 

501

713

1,082

 

Total assets

1,346

713

1,931

 

 

EQUITY

 

Capital and reserves attributable to the Company's equity shareholders

Called up share capital

477

327

477

Share premium account

1,409

851

1,409

Capital reserve

300

300

300

Translation reserve

(210)

(221)

(210)

Retained earnings

(1,183)

(632)

(967)

 

798

625

1,009

Convertible debt option reserve

189

-

189

Total equity

982

625

1,197

 

LIABILITIES

 

Non-current liabilities

Deferred tax liabilities

70

-

80

 

Current liabilities

Trade payables

81

66

225

Other payables

213

22

428

 

 

294

88

653

 

Total liabilities

364

88

733

 

Net assets

1,346

625

1,931

 

 

 

 

 

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT

 

 

 

6 months to

30 November 2014

6 months to

30 November 2013

Year to

31 May

2014

 

£'000

£'000

£'000

 

Cash flows from operating activities

Loss before tax

(229)

(122)

(471)

Adjustments for:

Cost of acquisition of subsidiaries

-

164

Share option and warrant charges

3

-

-

Finance charges

-

8

-

Depreciation and amortisation

91

-

-

Foreign exchange difference

-

(14)

3

(Increase)/decrease in trade receivables

(72)

-

-

Decrease/(increase) in other receivables

49

(2)

(80)

(Decrease)/increase in trade payables

(145)

(36)

57

Decrease in other payables

(217)

(412)

(155)

 

 

(291)

(456)

(11)

 

Net cash used in operating activities

(520)

(578)

(482)

 

Cash flows from investing activities

Purchase of tangible fixed assets

(6)

-

-

Purchase of intangible assets

(80)

-

-

Proceeds from sale of assets held for resale

-

940

940

Cash received on purchase of subsidiaries

-

-

65

Cash paid on acquisition of subsidiaries

-

-

(31)

Cash on acquisition of subsidiaries including costs

-

-

(164)

 

Net cash (used in)/generated from investing activities

(86)

940

810

 

Cash flows from financing activities

Interest paid

-

(8)

-

Loan repayment

-

-

(245)

Equity based loan received

-

-

189

Net proceeds from share issue

-

-

260

 

Net cash generated from financing activities

-

(8)

204

 

 

Net movement in cash and cash equivalents

(606)

354

532

Cash and cash equivalents at beginning of period

874

342

342

 

Cash and cash equivalents at end of period

268

696

874

 

 

 

 

 

 

 

 

 

 

FEEDBACK PLC

 

NOTES TO THE UNAUDITED INTERIM REPORT

 

 

 

1. BASIS OF PREPARATION

 

The consolidated interim financial statements have been prepared in accordance with the recognition and measurement principles of International Financial Reporting Standards as endorsed by the European Union ("IFRS") and expected to be effective at the year end of 31 May 2015. The accounting policies are unchanged from the financial statements for the year ended 31 May 2014.

 

The information set out in this interim report for the six months ended 30 November 2014 does not comprise statutory accounts within the meaning of section 434 of The Companies Act 2006. The results for the period ended 31 May 2014 are based on the published accounts for that period on which the auditors gave a report which did not contain statements under section 498 of the Companies Act 2006. The accounts for the period ended 31 May 2014 have been filed with the Registrar of Companies.

 

This interim report was approved by the directors on 13 February 2014.

 

 

2 LOSS PER SHARE

.

Basic earnings per share is calculated by reference to the loss on ordinary activities after and on the weighted average of shares in issue.

As at 30 November 2014

 

As at 30 November 2013

 

As at 31 May 2014

 

£'000

£'000

£'000

Net loss attributable to ordinary equity holders

(219)

 

(122)

(471)

As at 30 November 2014

 

As at 30 November 2013

 

As at 31 May 2014

Weighted average number of ordinary shares for basic earnings per share

190,746,746

 

 

130,946,746

132,912,773

Effect of dilution:

Share Options

-

-

-

Warrants

-

-

-

Weighted average number of ordinary shares adjusted for the effect of dilution

190,746,746

 

 

130,946,746

132,912,773

Loss per share (pence)

Basic

(0.11)

(0.09)

(0.35)

 

 

 

 

3 INTANGIBLE ASSETS

Software

Customer relationships

Patents

Goodwill

Total

£'000

£'000

£'000

£'000

£'000

Cost

At 31 May 2013

-

-

-

-

-

Additions

-

-

-

-

-

Disposed on sale of subsidiary

-

-

-

-

-

-

-

-

-

-

At 30 November 2013

Additions

20

-

-

-

20

Acquired with subsidiary

415

100

41

272

828

At 31 May 2014

435

100

41

272

848

Additions

64

-

16

-

80

At 30 November 2014

499

100

57

272

928

Amortisation

At 31 May 2013

-

-

-

-

-

Charge for the period

-

-

-

-

-

-

-

-

-

-

At 30 November 2013

Charge for the period

-

-

-

-

-

At 31 May 2014

-

-

-

-

-

Charge for the period

73

13

4

-

90

As at 31 November 2014

73

13

4

-

90

Net Book Value

30 November 2014

426

87

53

272

838

At 31 May 2014

435

100

41

272

848

At 30 November 2013

-

-

-

-

-

 

 

4 AVAILABILITY OF THE INTERIM REPORT

Copies of the report will be available from the Company's office and also from the Company's website www.fbk.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR TTMTTMBABTIA
Date   Source Headline
25th Mar 20247:00 amRNSNew tuberculosis partnership in India
21st Mar 20247:00 amRNSFurther CDC Pilot Programme Secured
23rd Feb 202411:03 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSHalf-year Report
21st Feb 20247:00 amRNSMedical Imaging Partnership Pilot Agreement
6th Feb 20247:00 amRNSNotice of Results & Investor Presentation
19th Dec 20237:01 amRNSHalf Year Trading Update
19th Dec 20237:00 amRNSAward of Pilot Funding
26th Oct 20232:24 pmRNSResult of AGM
25th Oct 20235:53 pmRNSDirector Dealing
27th Sep 202312:15 pmRNSNotice of AGM
12th Sep 20237:00 amRNSFinal Results
5th Sep 20237:00 amRNSNotice of Results & Investor Presentation
19th Jun 20237:00 amRNSYear End Trading Update
4th Apr 20237:00 amRNSBleepa-CareLocker contract extension with QVH
7th Feb 20237:00 amRNSHalf-year Report
3rd Feb 20233:56 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSNotice of Results, Analyst & Investor Presentation
22nd Dec 202212:08 pmRNSDirector/PDMR Shareholding: Correction
22nd Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20227:00 amRNSHalf Year Trading Update
1st Nov 20223:36 pmRNSTotal Voting Rights
13th Oct 20222:55 pmRNSResult of AGM & Proposed Share Consolidation
29th Sep 20223:46 pmRNSHolding(s) in Company
20th Sep 20223:26 pmRNSNotice of AGM & Proposed Share Consolidation
20th Sep 20227:00 amRNSFinal Results
13th Sep 20227:00 amRNSNotice of Results & Investor Presentation
6th Sep 20227:00 amRNS12 month contract for Sussex CDC pilot extension
19th Jul 20227:00 amRNSContract Update
16th Jun 20227:00 amRNSYear End Trading Update
1st Jun 20227:00 amRNSTrading Update & Director Appointment
12th May 202212:44 pmRNSChange of Registered Office
12th Apr 20227:00 amRNSBleepa wins two NHS Contract Awards
31st Mar 20227:00 amRNSBleepa TB Screening Pilot Now Live in Odisha
23rd Feb 20227:00 amRNSGrant of Options and PDMR dealing
10th Feb 20227:00 amRNSInterim Results
31st Jan 20227:00 amRNSNotice of Results
13th Dec 20217:00 amRNSPartnership with Amazon Web Services
6th Dec 20213:06 pmRNSHolding(s) in Company
2nd Dec 202110:20 amRNSDirector/PDMR Shareholding
2nd Dec 20219:54 amRNSHolding(s) in Company
1st Dec 20214:27 pmRNSHolding(s) in Company
1st Dec 20213:09 pmRNSHolding(s) in Company
30th Nov 20214:05 pmRNSHolding(s) in Company
29th Nov 20211:36 pmRNSDirector Appointment
29th Nov 20211:35 pmRNSResults of AGM, Open Offer, Issue of Equity & TVR
18th Nov 202112:15 pmRNSHolding(s) in Company
16th Nov 20214:35 pmRNSPrice Monitoring Extension
2nd Nov 20211:52 pmRNSResult of Placing
2nd Nov 20217:01 amRNSProposed Placing and Open Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.